Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites
Launched by ASAN MEDICAL CENTER ·
Trial Information
Current as of November 04, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment combination for people with advanced stomach cancer that has spread to the lining of the abdomen, causing fluid buildup called malignant ascites. The treatment combines three medicines—lenvatinib, nivolumab, and chemotherapy—to see if it can work better and be safe for these patients. The goal is to find out if this combination can help control the cancer and manage the fluid buildup.
People who might be eligible for this trial are adults with metastatic stomach cancer who have a moderate or higher amount of ascites (fluid in the abdomen). The study is open to all genders but is not recruiting yet. If you join the trial, you can expect to receive the combination of these medicines under careful medical supervision, with regular check-ups to monitor how you are doing and to watch for any side effects. This study is in an early phase, meaning researchers are still learning about the best way to use this treatment and how safe it is.
Gender
ALL
Eligibility criteria
About Asan Medical Center
Asan Medical Center, located in Seoul, South Korea, is a leading healthcare institution renowned for its commitment to advanced medical research and patient care. With a focus on innovative clinical trials, the center aims to enhance healthcare outcomes through rigorous scientific investigation and collaboration. Asan Medical Center is equipped with state-of-the-art facilities and a multidisciplinary team of experts dedicated to exploring new therapeutic approaches across various medical fields. Its robust infrastructure supports a wide range of clinical studies, contributing significantly to the global medical community's understanding of diseases and treatment efficacy.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported